HCA vs NAGE: fair value comparison
HCA Healthcare, Inc. and Niagen Bioscience, Inc. · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, HCA currently sits closer to the top of our discount ranking.
| HCA | NAGE | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $417.82 | $3.53 |
| 12-month range | $370.96–$532.92 | $3.33–$9.88 |
| Sector rank | #57 of 113 Healthcare | #62 of 113 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: HCA fair value analysis · NAGE fair value analysis